Congress trades
Humacyte, Inc. (HUMA)
About Humacyte, Inc.
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Laura E. Niklason
- Employees
- 184
- Listed since
- Dec 1, 2020
- Market value
- $97.3M
- Price to earnings
- -
- Earnings per share
- -$0.41
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 11, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 12, 2026 | -$0.16 | -$0.11 | $406K | $1.0M | EPS missRevenue miss |
| Q1 FY2026reported May 13, 2026 | -$0.09 | -$0.10 | $495K | $1.5M | EPS beatRevenue miss |
| Q4 FY2025reported Mar 27, 2026 | -$0.13 | -$0.13 | $467K | $1.3M | EPS in lineRevenue miss |
| Q3 FY2025reported Nov 12, 2025 | -$0.14 | -$0.17 | $753K | $923K | EPS beatRevenue miss |
| Q2 FY2025reported Aug 11, 2025 | -$0.24 | -$0.15 | $301K | $1.0M | EPS missRevenue miss |
| Q1 FY2025reported May 13, 2025 | $0.28 | -$0.19 | $517K | $765K | EPS beatRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Apr 28, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Laura E. NiklasonPresident and Chief Executive Officer | $634K | $0 | $4.6M | $5.2M |
| Dale A. SanderChief Financial Officer, Chief Corporate Development O | $546K | $383K | $1.2M | $2.1M |
| Shamik J. ParikhChief Medical Officer | $519K | $383K | $1.2M | $2.1M |
The summary compensation table from the 2025 proxy statement, current executives only. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Antipodes Partners Ltd | $7.9M | 10,103,647 | +76.5% | 4.31% |
| Vanguard Capital Management LLC | $7.9M | 10,107,679 | +41.2% | 4.32% |
| Alyeska Investment Group, L.P. | $4.7M | 6,022,925 | +100.0% | 2.57% |
| Davidson Kempner Capital Management LP | $3.9M | 5,000,000 | +100.0% | 2.14% |
| Blackrock, Inc. | $3.8M | 4,839,929 | -60.7% | 2.07% |
| Great Point Partners LLC | $2.9M | 3,750,000 | 0.0% | 1.60% |
| UBS Group AG | $2.2M | 2,843,493 | +2.2% | 1.21% |
| AQR Capital Management LLC | $2.0M | 2,597,134 | +34.9% | 1.11% |
| Geode Capital Management, LLC | $1.7M | 2,185,225 | -40.3% | 0.93% |
| Millennium Management LLC | $1.5M | 1,909,049 | +1665.1% | 0.82% |
| Susquehanna International Group, LLP | $1.3M | 1,699,243 | +60.6% | 0.73% |
| Citadel Advisors LLC | $1.1M | 1,443,376 | +100.0% | 0.62% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in HUMA
9 disclosures of 9 on record · median 25d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Tommy TubervilleJoint | Stock | Sale (Full) | $1,001 - $15,000 | -86.9%S&P +49.1% · vs S&P 500 -136.0% | May 3, 2024 | Jun 14, 2024 | 42d |
| Tommy TubervilleJoint | Stock | Sale (Partial) | $15,001 - $50,000 | -86.9%S&P +49.1% · vs S&P 500 -136.0% | May 3, 2024 | Jun 14, 2024 | 42d |
| Tommy TubervilleJoint | Stock | Sale (Partial) | $50,001 - $100,000 | -85.2%S&P +51.9% · vs S&P 500 -137.1% | Apr 30, 2024 | May 15, 2024 | 15d |
| Tommy TubervilleJoint | Stock | Purchase | $1,001 - $15,000 | -83.9%S&P +45.6% · vs S&P 500 -129.5% | Mar 21, 2024 | Apr 15, 2024 | 25d |
| Tommy TubervilleJoint | Stock | Purchase | $15,001 - $50,000 | -83.9%S&P +45.6% · vs S&P 500 -129.5% | Mar 21, 2024 | Apr 15, 2024 | 25d |
| Tommy TubervilleJoint | Stock | Purchase | $15,001 - $50,000 | -85.0%S&P +52.2% · vs S&P 500 -137.2% | Feb 12, 2024 | Mar 15, 2024 | 32d |
| Tommy TubervilleJoint | Stock | Sale (Partial) | $1,001 - $15,000 | -78.3%S&P +58.1% · vs S&P 500 -136.4% | Jan 19, 2024 | Feb 14, 2024 | 26d |
| Tommy TubervilleJoint | Stock | Purchase | $1,001 - $15,000 | -79.8%S&P +67.5% · vs S&P 500 -147.3% | Jul 25, 2023 | Aug 14, 2023 | 20d |
| Tommy TubervilleJoint | Stock | Purchase | $15,001 - $50,000 | -92.0%S&P +66.2% · vs S&P 500 -158.3% | Mar 30, 2022 | Apr 8, 2022 | 9d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Questions
Which members of Congress have traded HUMA?
Tommy Tuberville disclosed HUMA transactions in the filings shown here.
How quickly are HUMA trades disclosed?
Congressional disclosures took a median of 25 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.